3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

NCT01751451 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Abiraterone acetate
DRUG: Abiraterone acetate plus degarelix
DRUG: Degarelix

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]